<?xml version="1.0" encoding="UTF-8"?>
<p>Patients with MDS, as well as those with AML arising from MDS or other antecedent hematologic disease, may have had one prior regimen with a commercially available agent(s) for the treatment of prior hematologic disease. Prior therapy for AML was not permitted. Patients had to have adequate organ function, with an Eastern Cooperative Oncology Group performance status &lt;2 in order to receive intensive chemotherapy.</p>
